{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:38:42Z","timestamp":1788475122295,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.anai.2019.07.026","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T19:46:49Z","timestamp":1564775209000},"page":"476-482.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Long-term evaluation of response to omalizumab therapy in real life by a novel multimodular approach"],"prefix":"10.1016","volume":"123","author":[{"given":"Harjinder","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay I.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogeet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego J.","family":"Maselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2019.07.026_bib3","series-title":"CDC\u2019s National Asthma Control Program Grantees","year":"2013"},{"issue":"3","key":"10.1016\/j.anai.2019.07.026_bib5","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1398-9995.2004.00770.x","article-title":"The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma","volume":"60","author":"Bousquet","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2019.07.026_bib6","doi-asserted-by":"crossref","first-page":"1005e15","DOI":"10.1056\/NEJMoa1009705","article-title":"Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children","volume":"364","author":"Busse","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.anai.2019.07.026_bib7","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.rmed.2009.06.014","article-title":"\"Real-life\" effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study","volume":"103","author":"Brusselle","year":"2009","journal-title":"Respir Med"},{"issue":"8","key":"10.1016\/j.anai.2019.07.026_bib8","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.rmed.2009.03.008","article-title":"The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update","volume":"103","author":"Holgate","year":"2009","journal-title":"Respir Med"},{"issue":"9","key":"10.1016\/j.anai.2019.07.026_bib9","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.anai.2019.07.026_bib10","doi-asserted-by":"crossref","first-page":"1210e6","DOI":"10.1016\/j.jaci.2009.09.021","article-title":"Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma","volume":"124","author":"Lanier","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.07.026_bib11","doi-asserted-by":"crossref","first-page":"254e61","DOI":"10.1183\/09031936.01.00092101","article-title":"The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics","volume":"18","author":"Soler","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2019.07.026_bib12","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jaci.2017.03.002","article-title":"Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience","volume":"139","author":"Chipps","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.07.026_bib13","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.rmed.2013.04.017","article-title":"The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma","volume":"107","author":"Braunstahl","year":"2013","journal-title":"Respir Med"},{"issue":"11","key":"10.1016\/j.anai.2019.07.026_bib14","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.rmed.2005.10.004","article-title":"Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab","volume":"100","author":"Nowak","year":"2006","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.anai.2019.07.026_bib15","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/all.13302","article-title":"Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma","volume":"73","author":"Casale","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2019.07.026_bib16","first-page":"P3483","article-title":"Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: a pooled analysis","volume":"44","author":"Bousquet","year":"2014","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.anai.2019.07.026_bib17","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1111\/j.1398-9995.2009.02201.x","article-title":"Effects of omalizumab on markers of inflammation in patients with allergic asthma","volume":"64","author":"Holgate","year":"2009","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/j.anai.2019.07.026_bib18","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2019.07.026_bib19","author":"Casale"},{"issue":"7","key":"10.1016\/j.anai.2019.07.026_bib20","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.rmed.2007.01.011","article-title":"Predicting and evaluating response to omalizumab in patients with severe allergic asthma","volume":"101","author":"Bousquet","year":"2007","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.anai.2019.07.026_bib21","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1378\/chest.125.4.1378","article-title":"Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma","volume":"125","author":"Bousquet","year":"2004","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.anai.2019.07.026_bib22","doi-asserted-by":"crossref","first-page":"e0183869","DOI":"10.1371\/journal.pone.0183869","article-title":"The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: the ASTERIX observational study","volume":"12","author":"Bhutani","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.anai.2019.07.026_bib23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.anai.2011.06.005","article-title":"Development of the Asthma Control Composite outcome measure to predict omalizumab response","volume":"107","author":"Harris","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2019.07.026_bib24","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jaci.2011.12.962","article-title":"Development and validation of the Composite Asthma Severity Index\u2014an outcome measure for use in children and adolescents","volume":"129","author":"Wildfire","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2019.07.026_bib25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1398-9995.2010.02522.x","article-title":"Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma","volume":"66","author":"Bousquet","year":"2011","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2019.07.026_bib26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaci.2016.08.054","article-title":"A\u00a0randomized multicenter study evaluating Xolair persistence of response after long-term therapy","volume":"140","author":"Ledford","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2019.07.026_bib27","first-page":"45","article-title":"Most common, real life factors affecting effectiveness of omalizumab asthma treatment: a 10-year study","volume":"16","author":"Nurki\u0107","year":"2019","journal-title":"Med Glas (Zenica)"},{"key":"10.1016\/j.anai.2019.07.026_bib28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1081\/COPD-200053377","article-title":"Minimal clinically important differences in COPD lung function","volume":"2","author":"Donohue","year":"2005","journal-title":"COPD"},{"key":"10.1016\/j.anai.2019.07.026_bib29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1034\/j.1399-3003.1999.14a06.x","article-title":"What are minimal important changes for asthma measures in a clinical trial?","volume":"14","author":"Santanello","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2019.07.026_bib30","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2009.06.053","article-title":"The minimally important difference of the Asthma Control Test","volume":"124","author":"Schatz","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2019.07.026_bib31","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","article-title":"Omalizumab-induced reductions in mast cell Fc\u03b5RI expression and function","volume":"114","author":"Beck","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2019.07.026_bib32","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.4049\/jimmunol.158.3.1438","article-title":"Down-regulation of Fc(epsilon)RI expression on human basophils during in\u00a0vivo treatment of atopic patients with anti-IgE antibody","volume":"158","author":"MacGlashan","year":"1997","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.anai.2019.07.026_bib33","doi-asserted-by":"crossref","first-page":"8191","DOI":"10.1038\/srep08191","article-title":"Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis","volume":"5","author":"Lai","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.anai.2019.07.026_bib34","doi-asserted-by":"crossref","first-page":"AB13","DOI":"10.1016\/j.jaci.2015.12.041","article-title":"Impact of visit compliance on response to omalizumab therapy in a real-life clinical setting: reality study","volume":"137","author":"Singh","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2019.07.026_bib35","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12890-016-0290-5","article-title":"Drop-out rate among patients treated with omalizumab for severe asthma: literature review and real-life experience","volume":"16","author":"Caminati","year":"2016","journal-title":"BMC Pulm Med"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120619305460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120619305460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:22:46Z","timestamp":1761052966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120619305460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1081120619305460"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2019.07.026","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term evaluation of response to omalizumab therapy in real life by a novel multimodular approach","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2019.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}